What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

The POC testing market is set to reach $40 billion by 2022.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

The POC testing market is set to reach $40 billion by 2022.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

  • Method for the extraction of a vitamin K-dependent carboxylase complex and the use thereof. Sold to: Karl Thomae GmbH, Biberach, Germany.
  • Chemical compound used for prevention and/or treatment of arteriosclerosis, consisting of the following derivative of Menatetrenone as an active ingredient. Sold to: Eisai Co., Ltd. Tokyo, Japan.
  • Dietetic foods and pharmaceutical preparations inhibiting blood coagulation. Sold to: CPC-Europe, Heilbronn, Germany.
  • Method for immunological assaying of human Matrix Gla-Protein and its use as a biomarker. Sold to: IDS, Boldon, UK.
  • Compositions comprising vitamin K. Sold to Novartis, Basel, Switzerland.
  • Diagnostic assay for human matrix gla-protein and its use as a biomarker. Sold to: IDS, Boldon, UK.
  • Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification. Sold to: NattoPharma ASA, Hovik, Norway.
  • Vitamin K2 containing food product. Sold to: NattoPharma ASA, Hovik, Norway.
  • New delivery systems for vitamins and other trace elements to counteract deficiencies and to prevent chronic diseases. Withdrawn after publication.
  • Compositions comprising vitamin K for treating or preventing age-related stiffening of the arteries. Sold to: NattoPharma ASA, Hovik, Norway.
  • Pharmaceutical and nutraceutical products comprising vitamin K2. Sold to: NattoPharma ASA, Hovik, Norway.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com